Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.

doi:10.1111/ejh.12714

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.

European journal of haematology - 1 Sept 2016

Maurer Christian, Pflug Natali, Bahlo Jasmin, Kluth Sandra, Rhein Christina, Cramer Paula, Gross-Ophoff Carolin, Langerbeins Petra, Fink Anna-Maria, Eichhorst Barbara, Kreuzer Karl-Anton, Fischer Norbert, Tausch Eugen, Stilgenbauer Stephan, Böttcher Sebastian, Döhner Hartmut, Kneba Michael, Dreyling Martin, Binder Mascha, Hallek Michael, Wendtner Clemens-Martin, Bergmann Manuela, Fischer Kirsten

Abstract excerpt

PURPOSE: A phase I/II trial to assess safety and efficacy of the combination bendamustine, rituximab, and lenalidomide (BRL) in patients with chronic lymphocytic leukemia (CLL). PATIENTS AND METHODS: Seventeen relapsed or refractory (R/R) and five previously untreated (FL) CLL patients were enrolled in the trial. In the R/R cohort, four different dose levels of lenalidomide (maximum 15 mg/d) were used. In the FL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosome Aberrations

Share to Drug Administration Schedule

Share to Lenalidomide

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Maximum Tolerated Dose

Share to Rituximab

Share to Thalidomide

Source

Open in PubMed

Identifiers

PMID: 26643449
DOI: 10.1111/ejh.12714

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.PMID 26643449Read ↗

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.Semantic proximity Read ↗

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas.Semantic proximity Read ↗

Bendamustine alone or with rituximab modifies expression of apoptosis-regulating genes and proteins of CLL cells, depending on IGVH mutational status.Semantic proximity Read ↗

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.Semantic proximity Read ↗

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.Semantic proximity Read ↗

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.Semantic proximity Read ↗

Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non‐Hodgkin lymphoma: dose‐limiting myelosuppression without evidence of DNA hypomethylationSemantic proximity Read ↗

Dose-dense high-dose methylprednisolone and rituximab in the treatment of relapsed or refractory high-risk chronic lymphocytic leukemia.Semantic proximity Read ↗

Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.Semantic proximity Read ↗

A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.